Investigates anti-MRSA activity of novel hybrids, suggesting promising antibacterial leads.
A series of novel quinolone–aminopyrimidine hybrids were designed and synthesized through benzyl-position modification. Among them, A3 and A5 exhibited promising anti-MRSA activity, low cytotoxicity, and a low propensity for resistance development. Notably, A5 showed favorable metabolic stability in both HLMs and RLMs, whereas A3 displayed excessively prolonged half-lives, suggesting a potential risk of in vivo accumulation. Overall, A5 was identified as a promising lead compound for further antibacterial development.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: